AllDocs -> cancers

Journal of Cell and Molecular Biology 3: 51-119, 2004. Haliç University, Printed in Turkey. 51 Bladder tumor antigen sensitivity in bladder cancer patients Soner Güney, Serdar Arisan*, ‹brahim Duman, Turhan Çaflkurlu, Cem Sönmez, Erbil Ergenekon fiiflli Etfal Research and Training Hospital, 1 st Urology Clinics, fiiflli-Istanbul, Turkey (*author for correspondence) Received 19 December 2003; Accepted 26 January 2004 Abstract With its incidence continuing to increase, bladder cancer is now the fifth most common cancer in the world. Approximately half of these patients will have muscle-invasive disease at diagnosis and have distant metastasis within 2 years and 60% die within 5 years despite treatment. Therefore, rapid and sensitive urine based markers are still under investigation. In this study, we aim to find the BTA stat results for 259 Turkish patients (200 ...

Deaths at Home from Bladder Cancer (ISR) 2002-2004, All Ages by Strategic Health Authority (SHA) Notes Deaths at home from bladder cancer (ICD10 C67) Indirectly age-standardised rates (ISR) per 100 deaths (Standard rates are England annual age-specific rates 2002-04) All ages 2002-04 (Pooled) Data are based on the original underlying cause of death. Comments on numerator data - Information about the place of death is found on the mortality record in the communal establishment field. It contains one of: - A 5 digit code identifying a communal establishment or institution (e.g. hospital, nursing home, residential home); - An “H” code which indicates that the person is certified as having died at their home address and that this is not a communal establishment or; · An “E” code which indicates that the person died elsewhere. The communal establishments are themselves classified into 84 categories ...

doi:10.1136/jech.2005.038620 2006;60;168-172 J. Epidemiol. Community Health T Silverman Jay H Lubin, Margaret Karagas, Robert N Hoover, Joseph F Fraumeni, Jr and Debra Joseph D Ayotte, Dalsu Baris, Kenneth P Cantor, Joanne Colt, Gilpin R Robinson, Jr, England: an ecological study Bladder cancer mortality and private well use in New http://jech.bmjjournals.com/cgi/content/full/60/2/168 Updated information and services can be found at: These include: Data supplement http://jech.bmjjournals.com/cgi/content/full/60/2/168/DC1 "Web-only figure" References http://jech.bmjjournals.com/cgi/content/full/60/2/168#BIBL This article cites 18 articles, 2 of which can be accessed free at: Rapid responses http://jech.bmjjournals.com/cgi/eletter-submit/60/2/168 You can respond to this article at: service ...

All Persons Mortality from Bladder Cancer (SMR) 2002-2004, All Ages Notes Mortality from bladder cancer (ICD10 C67) Indirectly standardised ratios (SMR) All ages 2002-04 (Pooled) England 2002-04 = 100 (Standard rates are England annual age-specific rates 2002-04) Data are based on the original underlying cause of death. Data are based on the latest revisions of ONS population estimates for the respective years, current as of the 1st September 2005. Highlights At the local authority (LA) level bladder cancer mortality ratios were not significantly different from England Of these only three LA's had bladder cancer mortality lower than England; Luton UA, Watford CD and Hertsmere CD. For More Information Please Contact David Edwards, Public Health Intelligence Epidemiologist (david.edwards@phi-bedsherts.nhs.uk) Page 2 Source: National Statistics, Compendium ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BLADDER CANCER TISSUE ARRAY Catalog Number: TMA-132 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed ( Bladder carcinoma tissue array) Cases: 60 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: PCNA confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

1672 Main St. Ste. E #264 • Ramona, CA 92065 • Tel: 760.789.8928 • Fax: 760.789.8929 • Toll Free: 800.475.1955 • www.proteinbiotechnologies.com HUMAN BLADDER CANCER TISSUE ARRAY Catalog Number: TMA-133 Each dot represents a DISEASED tissue spot from one individual specimen that was selected and pathologically confirmed ( Bladder carcinoma tissue array) Cases: 63 Cores: 63 Diameter: 1.5mm Thickness: 5 µm Standard IHC: PCNA confirmed Layout : 7 x 9 1 2 3 4 5 6 7 8 9 A 1 2 3 4 5 6 7 8 9 B 10 11 12 13 14 15 16 17 18 C 19 20 21 22 23 24 25 26 27 D 28 29 30 31 32 33 34 35 36 ...

SANDIA REPORT SAND2004-1379P Unlimited Release Printed - January 2006 An Ecological Study of Arsenic-Related Bladder Cancer in U.S. Counties: Effects of Reference Populations and Confounders on the Calculated Risks Malcolm D. Siegel Prepared by Sandia National Laboratories Albuquerque, New Mexico 87185 and Livermore, California 94550 Sandia is a multiprogram laboratory operated by Sandia Corporation, a Lockheed Martin Company, for the United States Department of Energy’s National Nuclear Security Administration under Contract DE-AC04-94AL85000. Approved for public release; further dissemination unlimited. Page 2 Issued by Sandia National Laboratories, operated for the United States Department of Energy by Sandia Corporation. NOTICE: This report was prepared as an account of work sponsored by an agency of the United ...

Dear Colleagues: We are pleased to bring you the second and final edition of Bladder Cancer Options ™ : State-of-the-Art Patient Care . The content of the newsletter is based on a satellite symposium held at the Annual Meeting of the American Urological Association in San Antonio, Texas, May 2005. The cases we presented there were drawn from our own practices and illustrate some of the cutting-edge scientific perspectives in the field. In this edition, our panel discusses when to recommend conservative treatment or cystectomy for stage T1 grade 3 bladder cancer , how to manage BCG fever, treatment of refractory CIS, and how to approach coexistent prostate and bladder cancer . We also answer questions from the audience. We are grateful to The University of Texas M.D. Anderson Cancer Center for providing CME credits for this newsletter and to Schering-Plough Corporation for supporting this ...

Bladder Cancer Page 2 You may believe that bladder cancer is rare because you don’t hear much about it. Yet this form of cancer occurs more often than you might think. Bladder cancer is the fourth most common cancer among men and the ninth most common among women in the United States. Each year, more than 60,000 new cases of bladder cancer are detected, according to the American Cancer Society. Fortunately, most people with bladder cancer will not die of this disease. However, approximately 13,000 deaths are attributed to bladder cancer each year. Earlier diagnosis is important in reducing that number. If you don’t know the answers, read on! (Answer key is located inside back cover) A glossary of terms is also included at the end of this booklet. test your knowledge about If you or someone ...

Eleanor R Ray is a research fellow in urology in the Department of Urology at Guy’s and St Thomas’ Hospital. Her current research includes a randomised trial using photodynamic diagnosis in the investigation and treatment of superficial bladder cancer and a multicentre randomised trial, ODMIT-C, looking for reduced recurrence of transitional cell cancer (TCC) bladder following nephroureterectomy for TCC. She completed a three-year surgical rotation in South Wales and achieved an MRCS in 2004. She graduated with an MBBCh in 2000 from the University of Wales College of Medicine, having obtained a BSc in physiology in 1997 from Cardiff University. Tim S O’Brien is a Consultant Urological Surgeon at Guys and St Thomas’ Hospital. His clinical practice centres on the management of renal, bladder and testis cancer . His current research efforts ...

a report by Paula M J Moonen and J Alfred Witjes PhD Student of Oncological Urology, and Professor of Oncological Urology, Department of Urology, Radboud University Nijmegen Medical Centre Bladder cancer presents in approximately 70% of patients as superficial (pTa, pT1, pTis) disease. Super- ficial bladder cancer is characterised by a high recurrence rate (50% to 80%) despite treatment. A minority of patients will show progression to muscle- invasive and often lethal disease. Frequent follow-up is consequently necessary and is performed with the current gold standard – cystoscopy with cytology. Both techniques are not perfect. Cystoscopy is invasive and does not provide complete detection of multifocal lesions. Moreover, carcinoma in situ (CIS), character- istically high-grade aggressive and unpredictable, is often under-diagnosed. Cytology has ...

a report by Andreas Böhle Professor of Urology, Helios Agnes Karll Hospital Since 1976, the intravesical instillation of Bacillus Calmette-Guérin (BCG) has become a standard treatment for superficial bladder cancer (stages pTa, pT1 and carcinoma in situ (CIS)). Over the last decade, the incidence of bladder carcinoma has increased by 37%, while the mortality rate has decreased to 8% in the US. The most significant change with regard to bladder carcinoma during this time has been the introduction of intravesical immunotherapy into clinical routine. Therefore, this treatment may be considered as one of several factors contributing to the reduction in mortality. Therapeutic Efficacy of BCG in Urothelial Carcinoma In 1976, Morales, Eidinger and Bruce first published on the intravesical immunotherapy after superficial bladder cancer in humans. ...

INFILTRATIVE BLADDER CANCER AND UROLOGIC LAPAROSCOPY ESU Organized Course at the time of the national congress of the Morocco Association of Urology Place Marrakech, Morocco Date 13 May 2006 Chairman B. Djavan, Vienna (AT) Language the course language will be English PROGRAMME 09.00 Introduction B. Djavan, Vienna (AT) INVASIVE BLADDER CANCER 09.05 Prognostic factors and long term outcome of invasive bladder cancer M. Sheriff, Kent (GB) 09.25 Discussion 09.30 Radical cystectomy: tips and tricks G. Janetschek, Linz (AT) 09.50 Discussion 09.55 Orthotopic and heterotopic bladder reconstruction B. Djavan, Vienna (AT) 10.15 Discussion 10.20 – 10.40 Break LAPAROSCOPIC URO-ONCOLOGY 10.40 Laparoscopic nephrectomy: tips and tricks (VIDEO) M. Sheriff, Kent (GB) 11.05 Laparoscopic prostatectomy and cystectomy ...

Page 2 Bladder cancer in England 1998/9 to 2002/3. A geographical profile of hospital admissions. Authors: Michael Goldacre, David Yeates, Leicester Gill, Henry McGuinness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South East England Public Health Observatory, 2005 This document provides a geographical profile of hospital admission for bladder cancer in England. The geographical areas covered are the standard local authority areas of England. The period covered is April 1 1998 to March 31 2003. The data are from Hospital Episode Statistics (HES). HES includes data on all NHS hospital admissions (including admissions for day case care). This analysis includes HES data about men and women of all ages. The maps show: (a) The spell-based admission rates per 100,000 resident population for each local authority per ...

1 Pan Birmingham Cancer Network Transurethral Resection of Bladder Tumour (T.U.R.B.T) Patient Information Page 2 2 Introduction This booklet has been written to help you understand the surgery you are about to undergo. It is not meant to replace discussion between you and your Surgeon, but as a guide to be used together with what is discussed. If you have any questions or concerns, please do not hesitate to contact your Clinical Nurse Specialist. What is a bladder tumour? Your recent investigations have shown that there is a tumour inside your bladder which we suspect may be a type of cancer . There are 2 main types of bladder cancer : • Superficial bladder tumours - These tumours are confined to the inner lining of the bladder • Muscle invasive tumours - These tumours have spread to the ...

INTRODUCTION Few reports have been made on bladder tumors in young patients, and the prognosis in such cases is considered to be favorable. In the present case report, we describe a case of invasive transitional cell carcinoma of the bladder in a young female, who underwent total cystectomy. CASE REPORT The patient was a 27-year-old female whose profession was an insurance sales- woman. Her chief complaint was protein- uria. Neither her family history nor the past history was remarkable. She has smoked 10 cigarettes a day for 10 years. Since around April 1997, the patient had noticed macroscopic hematuria, but she had not consulted any doctor. She was subse- quently found to have proteinuria on regu- lar health check-up, and visited a physician at the Department of Internal Medicine in our hospital. Abdominal echography at that time suggested left hydronephrosis ...

Preston Hall Aylesford Kent ME20 7NJ Contact Press Office: Tel: 01622 713005/713014 Fax: 01622 713116 Paul.Bryden@kentmedway.nhs.uk Chairman: Kate Lampard Chief Executive: Marianne Griffiths Date: 20 December 2005 Way Forward Agreed for Prostate and Bladder Cancer Surgery Representatives from the nine PCTs in Kent and Medway met on the 19 th December 2005 to receive the considered views of the East Kent PCTs on the Michael Forrer report. Michael Forrer, an independent consultant was commissioned to review the impact on Kent and Canterbury Hospital, of the PCTs decision in May to centralise specialist prostate and bladder cancer surgery at Medway and Maidstone hospitals. The group noted East Kent PCTs view that even after the removal of this type of specialist surgery, the Urology Department at Kent and Canterbury could remain ...

1 Activity of (antibiotics and..) Com m only used agents in Bladder Cancer Ashish M . Kam at, M D D epartm ents of U rology and Cancer Biology Bladder Cancer Multidisciplinary Research Program Bladder SPORE Anti- Cancer Activity Com m only U sed Agents Estim ated U S Cancer D eaths* ONS=Other nervous system. Source: American Cancer Society, 2004. Men 290,890 Women 272,810 • 25% Lung & bronchus •15% Breast •10% Colon & rectum • 6% O vary • 6% Pancreas • 4% Leukem ia • 3% N on-H odgkin lym phom a • 3% U terine corpus • 2% M ultiple m yelom a • 2% Brain/O N S •24% A l other sites Lung & bronchus 32% Prostate 10% Colon & rectum 10% ...

GEORGE ELIOT HOSPITAL NHS TRUST DEPARTMENT OF UROLOGY Bladder Cancer Page 2 Bladder Cancer The bladder is a hollow muscular organ that stores urine and expels urine during voiding. A membrane made up of cells called transitional cells lines the bladder . Bladder cancer is a malignant tumour of this organ. As the lining is made of transitional epi- thelium, the tumours are commonly transitional cell carriers, though other forms of cancer like squamous cell cancer may occur. Causation Numerous chemicals are suspected bladder cancer forming agents, however; only cigarette smoking and occupational exposure to a certain class of organic chemicals called aromatic amines (beta- naphthylamines, xenylamine, 4-nirtobiphenyl, ben- zidine) are well-established risk factors. Bladder cancer due to aromatic ...

Incidence of Bladder Cancer by LA Notes Incidence of bladder cancer (ICD10 C67) Indirectly standardised registration ratios (SRR) All ages 1998-00 (Pooled) England 1998-00 = 100 (Standard rates are England annual age-specific rates 1998-00) Data are based on ONS population estimates (October 2004 revision). Highlights None of the Bedfordshire or Hertfordshire LA's had a higher incidence of bladder cancer than the national rate for England The incidence ratio was significantly lower than England in Mid Bedfordshire CD, Luton UA, Dacorum CD and Three Rivers CD FOR MORE INFORMATION Please contact David Edwards, Public Health Intelligence Specialist, PHIU (david.edwards@phi-bedsherts.nhs.uk) Page 2 Source:Compendium of Clinical and Health Indicators 2003 (Final Release 04/05) Incidence of Bladder Cancer (SRR with 95% CI), 1998-2000 Pooled, ...

Please see the first case discussion on page 3 Dear Colleagues: It is our pleasure to introduce you to the first of 2 issues of Bladder Cancer Options ™ : State-of-the- Art Patient Care . The content of the newsletter is based on a continuing medical education (CME) symposium held at the Annual Meeting of the American Urological Association in San Antonio, Texas, May 2005. The 3 cases presented here, for which I led the discussion, were drawn from our own practices and are meant to illustrate some of the dilemmas facing urologists in routine practice as well as the cutting-edge scientific perspectives in the field. Issue 2 contains 3 additional and equally stimulating cases for which the discussion was led by my esteemed colleague, Michael O’Donnell. State-of-the-art care for bladder cancer patients requires knowledge about the latest advances in all aspects of bladder cancer ...

FACTS ABOUT BLADDER CANCER The American Cancer Society estimates that more than 63,000 new cases of bladder cancer will be diagnosed in the United States this year. Seventy-five percent of these will be in men. In the United States, bladder cancer is the fourth most common cancer in men and eighth most common in women. The five-year survival rate for all types of bladder cancer is 82 percent. If the cancer is confined to the bladder (non-invasive), the survival rate is 94 percent. RISK FACTORS FOR BLADDER CANCER Bladder cancer is most often found in older white men, but it can be diagnosed in any- one at any age. Other risk factors include: Smoking tobacco products. Working in jobs where there is possible chemical expo- sure. For example, dye workers, textile workers, tire and rubber workers, painters, truck drivers, ...

A215- Urinary bladder cancer tissues (formalin fixed) For research use only Specifications: • No. of cases: 45 • Tissue type: Urinary bladder cancer tissues • No. of spots: 2 spots from each cancer case (90 spots) 4 non-neoplastic spots (4 spots) •Total spots: 94 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 6 7 8 9 10 11 A B C D E F G H I : Urothelial carcinoma : Urothelial carcinoma in situ : Adenocarcinoma + other pathology : Squamous carcinoma : Non-neoplastic Page 2 ...

What You Need To Know About Bladder Cancer NATIONAL INSTITUTES OF HEALTH National Cancer Institute ™ What You Need To Know About Index Page 2 This booklet is about bladder cancer . The Cancer Information Service can help you learn more about this disease. The staff can talk with you in English or Spanish. The number is 1–800–4– CANCER (1–800–422–6237). The number for deaf and hard of hearing callers with TTY equipment is 1–800–332–8615. The call is free. Este folleto es acerca del cáncer de la vejiga. Llame al Servicio de Información sobre el Cáncer para saber más sobre esta enfermedad. Este servicio tiene personal que habla español. El número a llamar es el 1–800–4– CANCER (1–800–422–6237). Personas con dificultades de audición ...

Annual Trends Bladder Cancer Incidence (SRR), 1993-2002, All Ages, by LA Notes Incidence of bladder cancer (ICD9 188, ICD10 C67) Indirectly standardised registration ratios (SRR) All ages 1993-2002 (Annual trends) England 2002 = 100 (Standard rates are England annual age-specific rates 2002) Data are based on ONS population estimates (October 2004 revision). Results may differ from those of previous Compendium issues because of changes in methodology to extract data by area, and also because of data enhancements by ONS. Highlights The annual incidence of bladder cancer in England declined between 1993 and 2002, with a sharper decline in incidence from 1999 onwards The incidence of bladder cancer at local authority level in Bedfordshire and Hertfordshire also declined between 1993 and 2002 Although the trend for bladder cancer in Bedford CD appeared to follow an upward trend between ...

Introduction The progress against bladder cancer over the last 20 years and the current diagnosis and treatment strategies for managing the disease have been the subject of many studies (Droller, 1998 and Sens et al ., 2000). Transitional cell carcinoma of bladder is the fourth most common cancer in men and the fifth in women. The number of cases O bjective : Metallothionein (MT) is a low molecular –weight protein with high affinity for heavy metals, and is believed to play an important role in tumorigenesis. The goals of this study were to define the expression of MT as a new marker in human transitional cell carcinoma (TCC), and to correlate its expression with histologic grade and growth pattern of the tumours. Methods : The study was performed on 46 tissue sections of TCC with different grades, 12 sections of chronic cystitis and 7 normal bladder mucosa using immunohistochemistry. ...

Introduction Bladder cancer accounts for approximately 5% of all human cancers and represents 95% of all urothelial tumors (Izadifar et al ., 1999). Transitional cell carcinomas (TCC) represent 90% of bladder cancer , while squamous cell carcinomas (SCC) account only for 3-7% (Cotran et al. , 1994). SCC of the bladder are uncommon in the developed countries; while in areas endemic for schistosomiasis, these O bjective: the present study aimed to investigate the pattern of expression of epidermal growth factor receptor (EGFR) and transforming growth factor a (TGF-a) in transitional cell carcinoma (TCC) and squamous cell carcinoma (SCC) of the urinary bladder and to correlate their expression with tumor grading. Methods: The work was performed on 28 cases of TCC and 12 cases of SCC using immunohistochemistry. Results: For both markers, positive staining reaction ...

Incidence of bladder cancer (ICD10 C67): NOTES Data is plotted for all persons Indirectly standardised registration ratios (SRR) England 1998-00 = 100 (Standard rates are England annual age-specific rates 1998-00) CAUTION Non-PCO level data are based on ONS population estimates (October 2004 revision). HIGHLIGHTS The incidence of bladder cancer was significantly lower than the incidence for England in the following local authorities: Mid-Bedfordshire CD, Luton UA, Dacorum CD, Three Rivers CD and Hertsmere CD FOR MORE INFORMATION Please contact David Edwards, Public Health Intelligence Specialist, PHIU (david.edwards@phi-bedsherts.nhs.uk) Page 2 Source: National Statistics, Compendium of Clinical and Health Indicators 2003 (Final Release 04/05) Incidence of Bladder Cancer (SRR with 95% CI) for all persons, 1998-2000 Pooled, All Ages 0 20 ...

Mortality from bladder cancer (ICD10 C67): NOTES Indirectly standardised ratios (SMR) England 2001-03 = 100 (Standard rates are England annual age-specific rates 2001-03) CAUTION Data are based on the original underlying cause of death. PCO level data are based on ONS population estimates (February 2005 release). HIGHLIGHTS At the PCT level bladder cancer mortality in Bedfordshire and Hertsfordshire is not significanlty different to the ratio for England FOR MORE INFORMATION Please contact David Edwards, Public Health Intelligence Specialist, PHIU (david.edwards@phi-bedsherts.nhs.uk) Page 2 Source: National Statistics, Compendium of Clinical and Health Indicators 2003 (Final Release 04/05) Mortality from Bladder Cancer (SMR with 95% CI), 2001-2003 Pooled, All Ages 0 20 40 60 80 100 120 140 160 180 ...

Summary of the Recommendation The U.S. Preventive Services Task Force (USPSTF) recommends against routine screening for bladder cancer in adults. D recommendation. The USPSTF found fair evidence that screening with available tests can detect bladder cancer in asymptomatic individuals. The potential benefit of screening would be small, at best, for the following reasons: there is fair evidence that many of the cancers detected by screening have a low tendency to progress to invasive disease; there is a relatively low overall prevalence of asymptomatic bladder cancer that would eventually lead to important clinical consequences; and there is limited evidence that early treatment of bladder cancer detected through screening improves long-term health outcomes. The potential harms of screening are at least small: screening tests have a low ...